HASPIN and primary effusion lymphoma: Sangivamycin may inhibit cellular kinases that are overexpressed in certain cancer cells, most notably protein kinase C (PKC) and haspin, which may have an apoptotic effect in certain cancer cell types [e.g., pancreatic cancer cells, breast cancer MCF-AR cells, and primary effusion lymphoma (PEL) cells] [54,55,56].